Prime medicine announces pricing of public offering

Cambridge, mass., july 30, 2025 (globe newswire) -- prime medicine, inc. (nasdaq: prme), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the pricing of an underwritten public offering of 38,000,000 shares of its common stock at a public offering price of $3.30 per share.
PRME Ratings Summary
PRME Quant Ranking